TABLE 3.

Hazard Ratios for Time to Discontinuation of Lubiprostone, Linaclotide, and Plecanatide Relative to Prucalopride During the Follow-Up Period

Time during the follow-up period	Time to index treatment discontinuationa (N = 14,700)
	Hazard ratiob (relative to prucalopride)	95% CI	P
At month 1
Lubiprostone	1.47	1.25-1.72	<0.001
Linaclotide	1.05	0.91-1.21	0.517
Plecanatide	1.07	0.91-1.27	0.414
At month 2
Lubiprostone	1.70	1.48-1.95	<0.001
Linaclotide	1.25	1.10-1.41	<0.001
Plecanatide	1.31	1.13-1.51	<0.001
At month 3
Lubiprostone	1.96	1.66-2.31	<0.001
Linaclotide	1.49	1.28-1.73	<0.001
Plecanatide	1.59	1.35-1.89	<0.001
At month 6
Lubiprostone	3.02	2.07-4.40	<0.001
Linaclotide	2.51	1.77-3.55	<0.001
Plecanatide	2.89	1.98-4.23	<0.001
At month 12
Lubiprostone	7.18	2.99-17.26	<0.001
Linaclotide	7.14	3.17-16.07	<0.001
Plecanatide	9.52	3.91-23.17	<0.001

Statistical significance set at P < 0.05.

^a Time to discontinuation was calculated as the time from the patient’s first prescription fill (index date) until a gap in treatment of at least 90 days.

^b Hazard ratios were calculated using a multivariate Cox regression model, controlling for confounding factors. The model was adjusted for age at index date, sex, geographical region, insurance plan type, selected comorbidities during the baseline period, constipation-related/gastroenterologist health care resource utilization during the baseline period, and constipation-related treatments used during the baseline period. In addition, the model included interaction terms between time and each of the 3 comparator medications. A hazard ratio of greater than 1.00 indicates a higher risk of treatment discontinuation occurring in the comparator medication group compared with the prucalopride group.